| Name | TRK-IN-17 |
|---|
| Description | TRK-IN-17 is a potent inhibitor of TRK. Tropomyosin-related kinases (Trks) are a family of receptor tyrosine kinases activated by neurotrophins, a group of soluble growth factors including Nerve Growth Factor (NGF), Brain-Derived Neurotrophic Factor (BDNF) and Neurotrophin-3 (NT-3) and Neurotrophin-4/5 (NT-4/5). TRK-IN-17 has the potential for the research of cancer diseases (extracted from patent WO2021148807A1, compound 3)[1]. |
|---|---|
| Related Catalog | |
| References |
[1]. Nicola ROBAS, et al. Pharmaceutical compositions and their uses. Patent WO2021148807A1. |
| Molecular Formula | C21H21F2N7S |
|---|---|
| Molecular Weight | 441.50 |